Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Has A Cleaner Recovery Angle, But With High Valuation
Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Olivier Loeillot CEO | XDUS Exchange | US7599161095 ISIN |
| US Country | 2,000 Employees | - Last Dividend | - Last Split | 26 Mar 1990 IPO Date |
Repligen Corporation is an innovative force in the biotechnological industry, primarily focusing on the development and commercialization of bioprocessing technologies and systems that play a crucial role in biological drug manufacturing. With a global reach that extends across North America, Europe, the Asia Pacific, and additional international markets, Repligen stands at the forefront of facilitating the production of biological drugs. The company, incorporated in 1981 and based in Waltham, Massachusetts, has established itself as a pivotal contributor to the biopharmaceutical and diagnostics sectors by offering a robust portfolio of products designed to enhance the efficiency and productivity of drug manufacturing processes. Through strategic collaboration agreements, such as with Navigo Proteins GmbH, Repligen continues to expand its technological arsenal, ensuring it remains synonymous with innovation and quality in the bioprocessing industry.